SRR1415095
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.542
- PANCREAS_BETA_CELLS+0.472
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.368
- FATTY_ACID_METABOLISM+0.359
- KRAS_SIGNALING_DN+0.329
- SPERMATOGENESIS+0.309
- ADIPOGENESIS+0.257
- BILE_ACID_METABOLISM+0.226
- MYOGENESIS+0.177
- PEROXISOME+0.158
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.585
- IL6_JAK_STAT3_SIGNALING-0.513
- INTERFERON_GAMMA_RESPONSE-0.490
- WNT_BETA_CATENIN_SIGNALING-0.484
- TNFA_SIGNALING_VIA_NFKB-0.416
- MITOTIC_SPINDLE-0.400
- INFLAMMATORY_RESPONSE-0.373
- ALLOGRAFT_REJECTION-0.360
- G2M_CHECKPOINT-0.357
- TGF_BETA_SIGNALING-0.319
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1437306 | GTEX | — | 0.994 |
| 2 | SRR1318426 | GTEX | — | 0.963 |
| 3 | SRR1471817 | GTEX | — | 0.929 |
| 4 | SRR1354689 | GTEX | — | 0.926 |
| 5 | SRR1368772 | GTEX | — | 0.924 |
| 6 | SRR1435020 | GTEX | — | 0.914 |
| 7 | SRR1420984 | GTEX | — | 0.908 |
| 8 | SRR1435293 | GTEX | — | 0.901 |
| 9 | SRR1402900 | GTEX | — | 0.900 |
| 10 | SRR807591 | GTEX | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.542 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.472 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.368 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.359 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.329 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.309 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.257 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.226 | Inavolisib | — uncovered |
| MYOGENESIS | 0.177 | Inavolisib | — uncovered |
| PEROXISOME | 0.158 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.128 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.059 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.051 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.029 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.026 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.003 | Inavolisib | — uncovered |